The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. (Q50114287)
Jump to navigation
Jump to search
scientific article published in March 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. |
scientific article published in March 2011 |
Statements
1 reference
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. (English)
1 reference
D B Geffen
1 reference
S Abu-Ghanem
1 reference
N Sion-Vardy
1 reference
R Braunstein
1 reference
M Tokar
1 reference
S Ariad
1 reference
B Delgado
1 reference
M Bayme
1 reference
M Koretz
1 reference
1 March 2011
1 reference
1 reference
22
1 reference
11
1 reference
2381-2386
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference